phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide has been researched along with norbinaltorphimine in 3 studies
| Studies (phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide) | Trials (phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide) | Recent Studies (post-2010) (phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide) | Studies (norbinaltorphimine) | Trials (norbinaltorphimine) | Recent Studies (post-2010) (norbinaltorphimine) |
|---|---|---|---|---|---|
| 276 | 0 | 55 | 918 | 0 | 205 |
| 7 | 0 | 5 | 918 | 0 | 205 |
| Protein | Taxonomy | phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide (IC50) | norbinaltorphimine (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0104 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.0029 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.212 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.024 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0036 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maier, SF; Mooney-Heiberger, K; Watkins, LR; Wiertelak, EP; Yang, HY | 1 |
| Ballet, S; Bourgoin, S; Braz, J; Cesselin, F; Hamon, M; Mauborgne, A; Zajac, JM | 1 |
| Chang, XM; Fang, Q; Han, ZL; Li, N; Li, XH; Pan, JX; Tang, HH; Wang, P; Wang, R; Wang, ZL; Zheng, T | 1 |
3 other study(ies) available for phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and norbinaltorphimine
| Article | Year |
|---|---|
The nature of conditioned anti-analgesia: spinal cord opiate and anti-opiate neurochemistry.
Topics: Analgesia; Analgesics; Animals; Conditioning, Classical; Endorphins; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Immune Sera; Injections, Spinal; Male; Morphine; Naltrexone; Narcotic Antagonists; Oligopeptides; Proglumide; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Spinal Cord | 1994 |
The neuropeptide FF analogue, 1DMe, reduces in vivo dynorphin release from the rat spinal cord.
Topics: Animals; Dose-Response Relationship, Drug; Dynorphins; Injections, Spinal; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Oligopeptides; Peptide Fragments; Perfusion; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Somatostatin; Spinal Cord | 2002 |
Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice.
Topics: Adamantane; Animals; Benzeneacetamides; Dipeptides; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Injections, Intraventricular; Male; Mice; Naltrexone; Nociception; Oligopeptides; Pyrrolidines | 2014 |